TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer

The identification of patients with metastatic triple-negative breast cancer (mTNBC) who are expected to benefit from platinum-based chemotherapy is of interest. We conducted a single-arm phase II clinical trial of single-agent platinum for mTNBC with biomarker correlates. Patients with mTNBC receiv...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical oncology 2015-06, Vol.33 (17), p.1902-1909
Hauptverfasser:	Isakoff, Steven J, Mayer, Erica L, He, Lei, Traina, Tiffany A, Carey, Lisa A, Krag, Karen J, Rugo, Hope S, Liu, Minetta C, Stearns, Vered, Come, Steven E, Timms, Kirsten M, Hartman, Anne-Renee, Borger, Darrel R, Finkelstein, Dianne M, Garber, Judy E, Ryan, Paula D, Winer, Eric P, Goss, Paul E, Ellisen, Leif W
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic Agents - administration & dosage Antineoplastic Agents - therapeutic use Biomarkers, Tumor - genetics BRCA1 Protein - genetics BRCA2 Protein - genetics Carboplatin - administration & dosage Carboplatin - therapeutic use Cisplatin - administration & dosage Cisplatin - therapeutic use Class I Phosphatidylinositol 3-Kinases Drug Administration Schedule Female Gene Expression Profiling Gene Expression Regulation, Neoplastic Genomic Instability Heterozygote Humans Loss of Heterozygosity Middle Aged Mutation Neoplasm Staging ORIGINAL REPORTS Phosphatidylinositol 3-Kinases - genetics Treatment Outcome Triple Negative Breast Neoplasms - drug therapy Triple Negative Breast Neoplasms - genetics Triple Negative Breast Neoplasms - pathology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!